Cover Image
市場調查報告書

B型血友病治療藥的全球市場:2015年∼2019年

Global Hemophilia B Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 341166
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
B型血友病治療藥的全球市場:2015年∼2019年 Global Hemophilia B Market 2015-2019
出版日期: 2015年09月30日 內容資訊: 英文 60 Pages
簡介

全球B型血友病治療藥市場預測從2014年到2019年將以4.18%的年複合成長率成長。

本報告提供全球B型血友病治療藥的市場相關調查,提供您市場概要,主要供應商所提供之產品,疾病的概要與發病趨勢,主要的開發平台候補藥的資料,收益規模的變化與預測,嚴重度及各治療法趨勢,各地區的收益佔有率,市場成長的各種影響因素分析,競爭環境,並彙整主要供應商簡介等資料。

第1章 摘要整理

  • 焦點

第2章 調查範圍

  • 市場概要
  • 主要供應商所提供之產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

  • 主要市場概況

第5章 市場環境

  • 市場概要
  • 市場規模·預測
  • 波特的五力分析

第6章 疾病概要

  • 關於疾病
  • 流行病學

第7章 產品研發線

  • 開發平台候補藥的主要資料

第8章 市場分析:嚴重度別

  • 輕度
  • 中度
  • 重度

第9章 市場分析:疾病管理別

  • 隨選 (出血的時候) 補充療法
  • 預防的補充療法
  • 抑制劑療法

第10章 地區分析

第11章 市場成長因素

第12章 市場成長因素的影響

第13章 市場課題

第14章 成長因素與課題的影響

第15章 市場趨勢

第16章 業者情勢

  • 競爭模式
  • M&A
  • 市場佔有率分析
  • 其他的有力供應商

第17章 主要供應商分析

  • Baxter
  • Grifols
  • Novo Nordisk
  • Pfizer

第18章 關於Technavio

圖表

目錄
Product Code: IRTNTR7234

About hemophilia B

Hemophilia B, also called the Christmas disease, is a blood coagulation disorder due to the deficiency or improper function of factor IX. It is inherited in an X-linked recessive pattern. This disorder is more prevalent in males than in females. Factor replacement therapies, mainly recombinant, are used in the treatment.

Technavio's analysts forecast the global hemophilia B market to grow posting a CAGR of 4.18% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global hemophilia B market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hemophilia B.

Technavio's report, Global Hemophilia B Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and landscape. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Baxter
  • Grifols
  • Novo Nordisk
  • Pfizer

Other Prominent Vendors

  • Alnylam
  • Amarna
  • Asklepios
  • Biogen
  • Catalyst Biosciences
  • CSL Behring
  • Dimension Therapeutics
  • Dong-A Scio
  • Emergent BioSolutions

Key market driver

  • Prophylactic treatment
  • For a full, detailed list, view our report

Key market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Key market trend

  • New technological advancements
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Disease overview

  • Understanding the disease
  • Epidemiology

PART 07: Pipeline portfolio

  • Key information of few pipeline candidates

PART 08: Market segmentation by disease severity

  • Mild hemophilia B
  • Moderate hemophilia B
  • Severe hemophilia B

PART 09: Market segmentation by disease management

  • On-demand therapy
  • Prophylactic therapy
  • Inhibitor therapy

PART 10: Geographical segmentation

PART 11: Market drivers

  • Focus on prophylactic treatment
  • Drugs with prolonged action
  • Patient assistance programs

PART 12: Impact of drivers

PART 13: Market challenges

  • High cost of therapy
  • Low diagnosis rate in developing countries
  • Complications of available therapies

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Advances in technology
  • Strategic alliances
  • Development of gene therapy products

PART 16: Vendor landscape

  • Competitive scenario
  • Mergers and acquisitions
  • Market share analysis 2014
  • Other prominent vendors

PART 17: Key vendor analysis

  • Baxter
  • Grifols
  • Novo Nordisk
  • Pfizer

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global hemophilia B market 2014-2019 ($ billions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Global cases of hemophilia B 2010-2013
  • Exhibit 05: Cases of Hemophilia B by region 2012
  • Exhibit 06: Cases of hemophilia B by region 2013
  • Exhibit 07: Global hemophilia B market segmentation by disease severity
  • Exhibit 08: Global hemophilia B market segmentation by disease severity 2014
  • Exhibit 09: Treatment of severe hemophilia B 2014
  • Exhibit 10: Global hemophilia B market segmentation by disease management
  • Exhibit 11: Share of prophylactic therapy by region 2014
  • Exhibit 12: Types of prophylaxis
  • Exhibit 13: Global hemophilia B market segmentation by disease management 2014
  • Exhibit 14: Global hemophilia B market segmentation 2014
  • Exhibit 15: Global hemophilia B market segmentation by revenue 2014 ($ billions)
  • Exhibit 16: Impact of drivers
  • Exhibit 17: Impact of drivers and challenges
  • Exhibit 18: Baxter: Global sales of hemophilia B drugs 2014-2017 ($ millions)
  • Exhibit 19: Baxter: Key takeaways
  • Exhibit 20: Grifols: Key takeaways
  • Exhibit 21: Novo Nordisk: Global sales of NovoSeven 2011-2014 ($ millions)
  • Exhibit 22: Novo Nordisk: Key takeaways
  • Exhibit 23: Pfizer: Global sales of BeneFIX 2011-2014 ($ millions)
  • Exhibit 24: Pfizer: Key takeaways
  • Exhibit 25: Novo Nordisk: Business segmentation by revenue 2014
  • Exhibit 26: Novo Nordisk: Business segmentation by revenue 2013 and 2014
  • Exhibit 27: Novo Nordisk: Geographical segmentation by revenue 2014
  • Exhibit 28: Novo Nordisk: R&D expenditure 2014
Back to Top